Please login to the form below
NOR-SWITCH
This page shows the latest NOR-SWITCH news and features for those working in and with pharma, biotech and healthcare.
Standing out in a crowd
explained. Switching. Once products reached the market Celltrion observed further challenges when it came to persuading physicians to switch patients from originator biologics to their biosimilar equivalents. ... This is despite work to study the effects
Latest news
-
Facing the new wave of biosimilars
One trial, the NOR-SWITCH study, has made a significant contribution to the evidence base for switching. ... Some policy makers have interpreted NOR-SWITCH results as confirmation of switching’s safety and efficacy.
-
Pfizer’s Remicade biosimilar receives Crohn's trial boost
In addition to existing data from the registration studies, real-world experience and the NOR-SWITCH trial, this data adds to the body of evidence supporting use of CT-P13 across ... That issue has already been studied to some extent in the NOR-SWITCH
-
NOR-SWITCH - the final piece in the biosimilar puzzle?
that policymakers do not misinterpret or exaggerate the findings of the NOR-SWITCH trial. ... NOR-SWITCH is designed to evaluate the effects of a switch from the original biologic to a biosimilar.
-
Study finds no problems switching from Remicade to biosimilar
The comparative trial - called NOR-SWITCH - was presented at the 2016 UEG Week in Vienna, Austria and showed that swapping from Remicade to a biosimilar version made by Celltrion posed no ... The data shows that safety and efficacy are maintained
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
